Key result
The PASCAL system achieved a similar rate of tricuspid regurgitation reduction by at least one grade at 30 days compared to the MitraClip-XTR system (91% vs. 96%, p=0.99).
Why the study?
Data comparing the performance of novel edge-to-edge devices, PASCAL and MitraClip-XTR, for transcatheter tricuspid valve repair in tricuspid regurgitation are scarce.
Does the PASCAL system compared to the MitraClip-XTR system improve tricuspid regurgitation reduction in high-surgical-risk patients with symptomatic tricuspid regurgitation?
Cohort (n=80)
No
Does the PASCAL system compared to the MitraClip-XTR system improve tricuspid regurgitation reduction in high-surgical-risk patients with symptomatic tricuspid regurgitation?
Absolute Event Rate: 91% vs 96%
p-value: p=0.99
Both the PASCAL and MitraClip-XTR edge-to-edge repair devices are feasible and provide comparable, effective reduction of tricuspid regurgitation in high-surgical-risk patients.
No takes yet. Share an insight, caveat, or question.
Similar success rates with PASCAL and MitraClip-XTR after PS matching; leaves open whether RCTs will confirm equivalence.
Sugiura et al. (2020) conducted a cohort in Tricuspid regurgitation (n=80). PASCAL transcatheter valve repair system vs. MitraClip-XTR system was evaluated on Reduction in tricuspid regurgitation severity by at least one grade at 30 days (p=0.99). The PASCAL system achieved a similar rate of tricuspid regurgitation reduction by at least one grade at 30 days compared to the MitraClip-XTR system (91% vs. 96%, p=0.99).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: